What is Validose?
Founded in 2016, Validose specializes in the creation of a smart, intranasal medical device. This technology leverages biometric analysis to precisely limit and control the dosage of controlled substances, a critical development aimed at mitigating prescription drug abuse. By integrating robust risk management solutions into its drug delivery product lines, Validose is positioning itself as a key player in the health technology sector, addressing a significant public health concern with innovative technological applications.
How much funding has Validose raised?
Validose has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2025): $2M with participation from Interstate Fusion Ventures and 10XBeta
Key Investors in Validose
Interstate Fusion Ventures
Interstate Fusion Ventures is an investment firm focused on connecting top-tier startups with resources and expertise, particularly bridging coastal innovation with Midwest capabilities to foster capital flow and talent exchange.
10XBeta
10XBeta Venture Studio streamlines HealthTech innovation by providing early capital, product development support, and in-house manufacturing to help startups commercialize ideas and scale efficiently.
What's next for Validose?
With the recent influx of major enterprise-level funding and a strategic investment, Validose is poised for significant expansion and further development of its groundbreaking intranasal medical device. This capital infusion is expected to accelerate product commercialization, enhance manufacturing capabilities, and broaden market penetration. The company's focus on reducing prescription drug abuse through advanced technology positions it for substantial growth and impact within the healthcare industry, potentially leading to further strategic partnerships and funding rounds as it scales its operations and impact.
See full Validose company page
